GlobalData on MSN7d
Spinogenix reports top line outcomes from trial of therapy for Fragile X syndromeUS-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback